In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers

A PET and MRI study

Michie Miyoshi, Hitoshi Shinotoh, Zbigniew K Wszolek, Audrey J. Strongosky, Hitoshi Shimada, Ryosuke Arakawa, Makoto Higuchi, Yoko Ikoma, Fumihiko Yasuno, Kiyoshi Fukushi, Toshiaki Irie, Hiroshi Ito, Tetsuya Suhara

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background: Microglial activation and disrupted neurotransmissions may herald symptomatic manifestations in neurodegenerative tauopathies. Methods: We investigated microglial activation with [ 11C]DAA1106 positron emission tomography (PET), striatal dopaminergic function with l-[β- 11C]dopa PET, acetylcholinesterase (AChE) activity with [ 11C]N-methylpiperidin-4-yl acetate PET, and morphologic brain changes with MRI in three persons (aged 38-41 years) with frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), who were presymptomatic gene carriers (PGCs) from an American kindred with pallidopontonigral degeneration. The results from these 3 PGCs were compared with [ 11C]DAA1106 PET results from age-matched 9 healthy volunteers (HV), and with l-[β- 11C]dopa and [ 11C]MP4A PET results from 10 HV. Values considered significant were more than 2 SDs greater or less than the normal control mean, as the number of subjects was small for group comparisons. Results: Glial activities were increased in the frontal cortex of one PGC, the occipital cortex of two PGCs, and the posterior cingulate cortex of one PGC, although none of the PGCs showed overt glial activation in the brain. Only one of the PGCs showed reduced AChE activity in the temporo-parietal cortex. Three PGCs showed low dopamine synthesis rates in the putamen. Hippocampal atrophy was observed in two PGCs. Conclusions: Hippocampal atrophy and striatal dopaminergic dysfunction may be early disease processes in the pathogenesis of FTDP-17. Neuroinflammation may also be an in vivo signature of tau pathology at a prodromal stage, although current PET techniques may not constantly reveal it as the earliest neuroimaging abnormality.

Original languageEnglish (US)
Pages (from-to)404-408
Number of pages5
JournalParkinsonism and Related Disorders
Volume16
Issue number6
DOIs
StatePublished - Jul 2010

Fingerprint

Positron-Emission Tomography
Mutation
Genes
Frontotemporal Dementia
Corpus Striatum
Dihydroxyphenylalanine
Acetylcholinesterase
Neuroglia
Atrophy
Healthy Volunteers
Tauopathies
Prodromal Symptoms
Occipital Lobe
Parietal Lobe
Chromosomes, Human, Pair 17
Putamen
Gyrus Cinguli
Brain
Frontal Lobe
Neuroimaging

Keywords

  • Acetylcholine
  • Dopamine
  • FTDP-17
  • Magnetic resonance imaging
  • Microglia
  • Positron emission tomography

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Clinical Neurology
  • Neurology

Cite this

In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers : A PET and MRI study. / Miyoshi, Michie; Shinotoh, Hitoshi; Wszolek, Zbigniew K; Strongosky, Audrey J.; Shimada, Hitoshi; Arakawa, Ryosuke; Higuchi, Makoto; Ikoma, Yoko; Yasuno, Fumihiko; Fukushi, Kiyoshi; Irie, Toshiaki; Ito, Hiroshi; Suhara, Tetsuya.

In: Parkinsonism and Related Disorders, Vol. 16, No. 6, 07.2010, p. 404-408.

Research output: Contribution to journalArticle

Miyoshi, M, Shinotoh, H, Wszolek, ZK, Strongosky, AJ, Shimada, H, Arakawa, R, Higuchi, M, Ikoma, Y, Yasuno, F, Fukushi, K, Irie, T, Ito, H & Suhara, T 2010, 'In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: A PET and MRI study', Parkinsonism and Related Disorders, vol. 16, no. 6, pp. 404-408. https://doi.org/10.1016/j.parkreldis.2010.04.004
Miyoshi, Michie ; Shinotoh, Hitoshi ; Wszolek, Zbigniew K ; Strongosky, Audrey J. ; Shimada, Hitoshi ; Arakawa, Ryosuke ; Higuchi, Makoto ; Ikoma, Yoko ; Yasuno, Fumihiko ; Fukushi, Kiyoshi ; Irie, Toshiaki ; Ito, Hiroshi ; Suhara, Tetsuya. / In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers : A PET and MRI study. In: Parkinsonism and Related Disorders. 2010 ; Vol. 16, No. 6. pp. 404-408.
@article{8810d1abfe3640dc9432b7bdff664248,
title = "In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: A PET and MRI study",
abstract = "Background: Microglial activation and disrupted neurotransmissions may herald symptomatic manifestations in neurodegenerative tauopathies. Methods: We investigated microglial activation with [ 11C]DAA1106 positron emission tomography (PET), striatal dopaminergic function with l-[β- 11C]dopa PET, acetylcholinesterase (AChE) activity with [ 11C]N-methylpiperidin-4-yl acetate PET, and morphologic brain changes with MRI in three persons (aged 38-41 years) with frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), who were presymptomatic gene carriers (PGCs) from an American kindred with pallidopontonigral degeneration. The results from these 3 PGCs were compared with [ 11C]DAA1106 PET results from age-matched 9 healthy volunteers (HV), and with l-[β- 11C]dopa and [ 11C]MP4A PET results from 10 HV. Values considered significant were more than 2 SDs greater or less than the normal control mean, as the number of subjects was small for group comparisons. Results: Glial activities were increased in the frontal cortex of one PGC, the occipital cortex of two PGCs, and the posterior cingulate cortex of one PGC, although none of the PGCs showed overt glial activation in the brain. Only one of the PGCs showed reduced AChE activity in the temporo-parietal cortex. Three PGCs showed low dopamine synthesis rates in the putamen. Hippocampal atrophy was observed in two PGCs. Conclusions: Hippocampal atrophy and striatal dopaminergic dysfunction may be early disease processes in the pathogenesis of FTDP-17. Neuroinflammation may also be an in vivo signature of tau pathology at a prodromal stage, although current PET techniques may not constantly reveal it as the earliest neuroimaging abnormality.",
keywords = "Acetylcholine, Dopamine, FTDP-17, Magnetic resonance imaging, Microglia, Positron emission tomography",
author = "Michie Miyoshi and Hitoshi Shinotoh and Wszolek, {Zbigniew K} and Strongosky, {Audrey J.} and Hitoshi Shimada and Ryosuke Arakawa and Makoto Higuchi and Yoko Ikoma and Fumihiko Yasuno and Kiyoshi Fukushi and Toshiaki Irie and Hiroshi Ito and Tetsuya Suhara",
year = "2010",
month = "7",
doi = "10.1016/j.parkreldis.2010.04.004",
language = "English (US)",
volume = "16",
pages = "404--408",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers

T2 - A PET and MRI study

AU - Miyoshi, Michie

AU - Shinotoh, Hitoshi

AU - Wszolek, Zbigniew K

AU - Strongosky, Audrey J.

AU - Shimada, Hitoshi

AU - Arakawa, Ryosuke

AU - Higuchi, Makoto

AU - Ikoma, Yoko

AU - Yasuno, Fumihiko

AU - Fukushi, Kiyoshi

AU - Irie, Toshiaki

AU - Ito, Hiroshi

AU - Suhara, Tetsuya

PY - 2010/7

Y1 - 2010/7

N2 - Background: Microglial activation and disrupted neurotransmissions may herald symptomatic manifestations in neurodegenerative tauopathies. Methods: We investigated microglial activation with [ 11C]DAA1106 positron emission tomography (PET), striatal dopaminergic function with l-[β- 11C]dopa PET, acetylcholinesterase (AChE) activity with [ 11C]N-methylpiperidin-4-yl acetate PET, and morphologic brain changes with MRI in three persons (aged 38-41 years) with frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), who were presymptomatic gene carriers (PGCs) from an American kindred with pallidopontonigral degeneration. The results from these 3 PGCs were compared with [ 11C]DAA1106 PET results from age-matched 9 healthy volunteers (HV), and with l-[β- 11C]dopa and [ 11C]MP4A PET results from 10 HV. Values considered significant were more than 2 SDs greater or less than the normal control mean, as the number of subjects was small for group comparisons. Results: Glial activities were increased in the frontal cortex of one PGC, the occipital cortex of two PGCs, and the posterior cingulate cortex of one PGC, although none of the PGCs showed overt glial activation in the brain. Only one of the PGCs showed reduced AChE activity in the temporo-parietal cortex. Three PGCs showed low dopamine synthesis rates in the putamen. Hippocampal atrophy was observed in two PGCs. Conclusions: Hippocampal atrophy and striatal dopaminergic dysfunction may be early disease processes in the pathogenesis of FTDP-17. Neuroinflammation may also be an in vivo signature of tau pathology at a prodromal stage, although current PET techniques may not constantly reveal it as the earliest neuroimaging abnormality.

AB - Background: Microglial activation and disrupted neurotransmissions may herald symptomatic manifestations in neurodegenerative tauopathies. Methods: We investigated microglial activation with [ 11C]DAA1106 positron emission tomography (PET), striatal dopaminergic function with l-[β- 11C]dopa PET, acetylcholinesterase (AChE) activity with [ 11C]N-methylpiperidin-4-yl acetate PET, and morphologic brain changes with MRI in three persons (aged 38-41 years) with frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), who were presymptomatic gene carriers (PGCs) from an American kindred with pallidopontonigral degeneration. The results from these 3 PGCs were compared with [ 11C]DAA1106 PET results from age-matched 9 healthy volunteers (HV), and with l-[β- 11C]dopa and [ 11C]MP4A PET results from 10 HV. Values considered significant were more than 2 SDs greater or less than the normal control mean, as the number of subjects was small for group comparisons. Results: Glial activities were increased in the frontal cortex of one PGC, the occipital cortex of two PGCs, and the posterior cingulate cortex of one PGC, although none of the PGCs showed overt glial activation in the brain. Only one of the PGCs showed reduced AChE activity in the temporo-parietal cortex. Three PGCs showed low dopamine synthesis rates in the putamen. Hippocampal atrophy was observed in two PGCs. Conclusions: Hippocampal atrophy and striatal dopaminergic dysfunction may be early disease processes in the pathogenesis of FTDP-17. Neuroinflammation may also be an in vivo signature of tau pathology at a prodromal stage, although current PET techniques may not constantly reveal it as the earliest neuroimaging abnormality.

KW - Acetylcholine

KW - Dopamine

KW - FTDP-17

KW - Magnetic resonance imaging

KW - Microglia

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=77953614566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953614566&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2010.04.004

DO - 10.1016/j.parkreldis.2010.04.004

M3 - Article

VL - 16

SP - 404

EP - 408

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - 6

ER -